Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder
characterized by fluctuating muscle weakness and fatigue. Acetylcholinesterase
inhibitors, thymectomy, and immunosuppressive treatments are the mainstays of
traditional MG care. However, these therapies frequently have serious drawbacks and
adverse effects. Secondary Plant Metabolites (SPMs) have been shown to hold promise
as alternative or supplementary therapies for Myocardial Infarction (MI) in recent
developments in the field of phytotherapy. Flavonoids, alkaloids, terpenoids, and
phenolic compounds are examples of SPMs. These chemicals have antioxidant,
immunomodulatory, and anti-inflammatory qualities that may be advantageous to MG
patients. The most recent studies on different SPMs and their modes of action with MG
are examined in this chapter. Research has demonstrated that substances like quercetin,
resveratrol, and curcumin can improve neuromuscular transmission, lower oxidative
stress, and regulate immunological responses, all of which may help to lessen MG
symptoms. Furthermore, preclinical and clinical studies have started to confirm the
safety and effectiveness of these metabolites, opening the door for novel treatment
approaches. Including SPMs in the MG treatment plan may improve patient outcomes,
decrease dependency on prescription drugs, and minimize adverse effects. This chapter
aims to provide a comprehensive overview of the current state of knowledge and future
directions in the use of secondary plant metabolites for regulating myasthenia gravis,
with an emphasis on their participation in innovative and comprehensive therapy
techniques.
Keywords: Immune modulation, Innovative therapies, Myasthenia Gravis, Neuromuscular transmission, Phytotherapy, Plant metabolites.
